Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota June 11, 2018 By CKD Digital
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota June 11, 2018 By CKD Digital
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks
